Nuvectis Pharma, Inc. — Director's Dealing 2022

Jun 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-06-22

Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-22	Common Stock	P	100	$13.10	Acquired	2963714	Direct
2022-06-23	Common Stock	P	200	$11.40	Acquired	2963914	Direct
2022-06-24	Common Stock	P	400	$12.18	Acquired	2964314	Direct

Footnotes

F1: Includes 96,759 shares of restricted stock and 120,000 restricted stock units.

F2: Reflects the weighted average purchase price. The range of prices for the shares purchased was $12.01 to $12.34. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.